

Rev04 DATASHEET

Update: May,04,2023

IL-16, Human

Cat. No.: Z02196

Product Introduction

| Species | Human | |
|---------------------------|--|--|
| Protein Construction | IL-16 (Met1203-Ser1332) Accession # Q14005 | |
| Purity | > 95% as analyzed by SDS-PAGE | |
| Endotoxin Level | < 1 EU/µg of protein by LAL method | |
| Expression System | E. coli | |
| Apparent Molecular Weight | 18-20 kDa, on SDS-PAGE under reducing conditions. | |
| Formulation | Lyophilized from a 0.2 μm filtered solution in 20 mM PB, 150 mM NaCl, pH 7.0. | |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 $\mu g/ml$. | |
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. | |

Background

Target Background : IL-16 is a CD8⁺ T cell-derived cytokine that induces chemotaxis of CD4⁺ T cells and CD4⁺ monocytes and eosinophils. Analysis by gel filtration suggests that, under physiological conditions, human IL-16 exists predominantly as a noncovalently linked multimer, but that some IL-16 may exist as a monomer. However, only the multimeric form appears to possess chemotactic activity, suggesting that receptor cross-linking may be required for activity. IL-16 also induces expression of IL-2 receptor (IL-2R) and MHC class II molecules on CD4⁺ T cells. Human and murine IL-16 show significant cross-species reactivity.

Synonyms: IL16; LCF; NPRprIL-16; IL-16; interleukin 16

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

生产商: 南京金斯瑞生物科技有限公司 江苏省南京市江宁区科学园雍熙路28号



| Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China | | | | |
|--|--|--|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |